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Abstract Ecto-ATPase activities of melanocytes and human
melanoma cell lines differing in the stage of progression were
compared. A dramatic increase in ecto-ATPase activity above
the level of normal melanocytes was demonstrated in the
differentiated melanomas and was followed by a gradual
decrease with tumor progression. The characteristics of this
enzymatic activity were consistent with CD39/ecto-ATP diphos-
phohydrolase (ATPDase) which was found to be the major ecto-
ATP-hydrolysing enzyme in melanomas. Indeed, the expression
of CD39 and the level of CD39 mRNA followed a similar
pattern. Since CD39 is known to regulate homotypic adhesion
and, supposedly, affects the disaggregation step, we suggest that
overexpression of CD39 may enable tumor cells to reduce
contacts with T-lymphocytes and escape from immunological
recognition.
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1. Introduction
Sporadic cutaneous melanoma is a cancer form with high
mortality, despite of its capacity to induce a speci¢c immune
response [1]. Analysis of the genetic defects leading to disrup-
tion of the mechanisms of the intracellular control of the
mammalian cell cycle [2,3] or defects on the antigen presenta-
tion pathway potentially enabling immune escape of tumor
cells [4] are of importance for understanding the melanoma
pathogenesis. Several common features of tumorigenesis, such
as impaired cell-cell communication, adhesion and signal
transduction, often result from changes in the components
exposed on the cell surface.
Extracellular ATP is becoming recognized as a cell-cell
communication molecule which acts via purinergic receptors
[5] and various widely distributed nucleotide-hydrolysing ecto-
enzymes [6]. CD39, originally described as a marker of acti-
vated immunocompetent cells and somehow involved in ho-
motypic adhesion [7], was recently shown to be one of numer-
ous extracellular nucleotide-hydrolysing enzymes, ecto-ATP
diphosphohydrolase (ATPDase, 3.6.1.5) [8], thus, exhibiting
both ATPase and ADPase activities. Here, we report that
(1) di¡erentiated, but not progressed melanomas show an in-
crease in ecto-ATPase activity above the level found in normal
melanocytes; (2) CD39 is the major ecto-ATP-hydrolysing
enzyme in melanomas and follows the same pattern of expres-
sion as does the enzymatic activity; (3) the level of CD39
mRNA transcripts follows both the enzymatic activity and
CD39 expression, pointing to transcriptional regulation of
expression of CD39 in relation to the state of tumor progres-
sion. CD39 might therefore be considered a marker of mela-
noma di¡erentiation. A hypothesis associating the overexpres-
sion of CD39 with the escape of tumor cells from
immunological e¡ector mechanisms at early steps of tumor
progression is proposed.
2. Materials and methods
2.1. Cell lines
Normal melanocytes were purchased from Clonetics (USA). Mela-
noma cell lines were established as has been described previously [9]
using tumor samples obtained from patients who underwent surgery
for primary and metastatic melanoma at the Department of Plastic
Surgery, Rigshospitalet (Copenhagen, Denmark). All melanoma cells
(except FM3 sublines) were used at early passages in culture (no more
than 10). The FM3 sublines FM3.D (di¡erentiated) and FM3.P (prog-
ressed) di¡ering in their state of di¡erentiation have been described
previously [10]. K562 erythroleukemic cells and EBV-transformed JY
lymphoblastoid cells were used as controls with known low and high
levels of CD39 expression, respectively [7]. All cells were grown in
RPMI 1640 medium (Gibco Laboratories, Grand Island, NY, USA)
supplemented with 10% heat inactivated fetal calf serum. The mean
cell size was determined using a Coulter Multisizer II (Coulter Elec-
tronics Ltd., Northwell Drive, England).
2.2. Antibodies and £ow cytometric analysis
Unconjugated monoclonal antibodies (mABs) against CD39 (clone
A1) were purchased from Zymed Laboratories, Inc. (San Francisco,
CA, USA). Goat anti-mouse FITC-labeled F(abP)2 fragments were
used as the secondary antibodies. Flow cytometric analyses were car-
ried out using a FACScan £ow cytometer (Becton Dickinson, Immu-
nocytometry Systems, San Jose, CA, USA).
2.3. Determination of ecto-ATPase activity
Cells from semi-con£uent monolayers were harvested by trypsin-
EDTA treatment, to which ecto-ATPase activity was shown to be
resistant. Cells were washed twice with assay medium consisting of
20 mM HEPES, 10 mM glucose, 150 mM NaCl, 2 mM CaCl2, pH
7.5, and suspended in the same medium at a concentration of 0.5^
1.0U106 cells/ml. Aliquots were withdrawn for cell counting in Coult-
er Multisizer II enabling also to evaluate viability of the cells. Rou-
tinely, duplicate samples of 0.1 ml of cell suspension were added to
the assay medium containing ATP, so that the ¢nal substrate concen-
tration was 1 mM. Samples were incubated for 30 min at 37‡C. Sub-
sequently the cells were sedimented, and the amount of Pi released
from ATP was determined in the supernatants using two colorimetric
procedures [11,12], modi¢ed as described previously [13]. Two values
^ non-enzymatic Pi release from ATP into assay medium during in-
cubation without cells, and Pi content in samples incubated without
ATP ^ were subtracted from the total Pi release giving values for the
enzymatic ATP hydrolysis. KH2PO4 was used as Pi standard. The
speci¢c activity was expressed as mU/106 cells, where mU is release
of one nmol Pi per min at 37‡C. The same procedure was employed,
when other nucleotide triphosphates and ADP were used as sub-
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strates. Intactness of the cells was evaluated by measuring Na,K-
ATPase activity [14] detectable only in disrupted cells. Melanoma or
EBV-transformed B cells (approximately 2.5U105) were incubated for
1.5 h at 37‡C in 0.2 ml of growth medium in absence or in the
presence of 1 Wg mABs either to CD39 or to unrelated antigen biotin.
Subsequently, cells were sedimented, washed with assay medium and,
after cell counting the enzymatic activity was determined as described
above. All the reagents were from Sigma Chemical Co. (St. Louis,
MO, USA) if not indicated otherwise.
2.4. RT-PCR
RNA was extracted using the Purescript Isolation Kit (Gentra).
cDNA synthesis was carried out using 1^3 Wg of total RNA with
oligo-dT and M-MLV SuperScript II reverse transcriptase (Gibco-
BRL, Life Technologies Inc., Gaithersburg, MD, USA) as described
[4]. Serial dilutions of cDNA were ampli¢ed in the PCR ampli¢cation
containing the following in 1UPCR bu¡er (50 mM KCl, 20 mM Tris
pH 8.4, 2.0 mM MgCl2, 0.2 mM cresol, 12% sucrose, 0.005% (w/v)
BSA (Boehringer-Mannheim, Mannheim, Germany): 40 WM of
dNTPs (Pharmacia LKB, Uppsala, Sweden), 2.0 units of AmpliTaq
polymerase (Perkin Elmer Cetus Corporation, Emeryville, CA, USA)
and 2.5 pmol of each primer. The primers used amplify the cDNA
fragments of glyceraldehyde-3-phosphate dehydrogenase, GADPH
(5P-AGGGGGGAGCCAAAAGGG-3P and 5P-GAGGAGTGGGT-
GTCGCTGTTG-3P ; 540 bp) and of CD39 (5P-TTTGGAGCTTTG-
GACCTTGG-3P and 5P-GGGGGTCTTGTAAAGGTCACTTA-3P ;
275 bp). The parameters used for the ampli¢cation were 94‡C for
30 s, 60‡C for 30 s and 72‡C for 30 s for 26 or 30 cycles (GAPDH
and CD39 respectively).
3. Results
Characteristics of the sublines FM3.D and FM3.P derived
from the melanoma cell line FM3 have been described previ-
ously [10]. According to these characteristics, the FM3.D and
FM3.P sublines di¡er in their stage of tumor progression.
FM3.D is a di¡erentiated variant of FM3 melanoma cells,
while the FM3.P subline has all the characteristics of pro-
gressed melanoma cells. Subline FM3.D/40 is a di¡erentiated
FM3.D subline between passages 40 and 50. This subline has
lost some of the di¡erentiation properties (less pigmented) and
acquired a high proliferation rate, but the other characteristics
are similar to those of FM3.D. The mean sizes of melanocytes
and melanoma FM3.D and FM3.D/40 sublines, as determined
by Coulter Multisizer II, were 16.17 Wm, 18.81 Wm and 18.09
Wm, respectively, and did not change further during progres-
sion to FM3.P cells. Fig. 1 illustrates the hydrolysis in Ca2-
containing medium of extracellularly added ATP by normal
melanocytes and three FM3 melanoma sublines. Values for
the enzymatic activity exhibited by cultured normal melano-
cytes (1.4 þ 0.15 mU/106 cells) were rather low, consistent with
the observation in vivo, that in epidermal layers only the
Langerhans cells exhibit histochemically detectable ecto-AT-
Pase activity [15]. A drastic increase of ecto-ATPase activity
was observed in the FM3.D subline, representing the most
di¡erentiated variant of FM3 melanoma cells. The ecto-AT-
Pase activity gradually declines to the initial level of normal
melanocytes or lower during melanoma progression. The
characteristics of the enzymatic activity are similar in all cell
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Fig. 1. Ecto-ATPase activity and CD39 expression of melanocytes
and FM3 sublines di¡ering in their state of progression. Ecto-AT-
Pase activity of intact cells was determined at 37‡C in 20 mM
HEPES, pH 7.5, containing 10 mM glucose, 150 mM NaCl, 2 mM
CaCl2 and 1 mM ATP, and enzymatic release of Pi from ATP dur-
ing incubation with the cells was measured. CD39 expression was
analyzed by £ow cytometry and shown as di¡erence between mean
£uorescence intensity of bound FITC-labeled secondary antibodies
in the presence and absence of the primary antibodies. Ecto-ATPase
activity was determined in ¢ve independent experiments, in three of
them CD39 expression was analyzed simultaneously. Mean val-
ues þ S.D. (bars) are shown.
Table 1
Nucleotide speci¢city and the e¡ect of some inhibitors on ecto-ATPDase activity on FM3.D/40 melanoma cell subline
Substrate Inhibitors Nucleotide-hydrolysing activity,
% of control with ATP
Ca2-containing medium
ATP 100
UTP 109.1 þ 4.7
CTP 95.6 þ 3.3
GTP 91.0 þ 1.4
ADP 0.2 mM AP5A 57.4 þ 5.2
ADP 0.2 mM AP5A+10 mM NaN3 30.1 þ 2.2
ATP 10 mM NaN3 65.5 þ 2.5
ATP 1 mM levamisole 96.0 þ 5.2
ATP 0.1 mM vanadate+1 mM ouabain+10 WM oligomycin 89.4 þ 2.6
ATP control mABs 94.2 þ 3.4
ATP mABs to CD39 71.0 þ 2.3
Mg2-containing medium
ATP 0.1 mM vanadate+1 mM ouabain+10 WM oligomycin 94 þ 3.1
ATP 5 mM EDTA 2.5 þ 0.4
Assay medium contained 20 mM HEPES, 150 mM NaCl, 2 mM CaCl2 or MgCl2, pH 7.5, substrates at concentration 1 mM and inhibitors at the
indicated concentrations. Values are means þ S.D. of ¢ve independent experiments. Speci¢c activity in Ca2-containing medium with ATP as a
substrate, 18.4 mU/106 cells, corresponds to 100%.
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lines (data not shown) and are exempli¢ed in Table 1 for the
cell line FM3.D/40. All tested nucleotide triphosphates were
hydrolysed almost equally e⁄ciently and ADP was also hy-
drolysed. Hydrolysis of ADP, in the presence of the adenylate
kinase inhibitor Ap5A (added to prevent ATP formation) was
57% of ATP hydrolysis. For comparison, speci¢c activity of
5P-nucleotidase in FM3.D/40 cells determined with 1 mM ex-
tracellular AMP was 2.3 mU/106 cells, i.e. 8-fold lower than
ATPase activity (not shown). Common inhibitors of P- and
F1-FO-type membrane ATPases and some phosphatases (so-
dium orthovanadate, oligomycin and ouabain) did not signi¢-
cantly in£uence ecto-ATPase activities, either when used sep-
arately (not shown) or combined (Table 1). Levamisole, an
inhibitor of alkaline phosphatase, also was found not to be
inhibitory. Taken together, these results indicated that in in-
tact cells there was no signi¢cant contribution to measured
ecto-ATPase activity from other membrane nucleotide-hydro-
lysing enzymes. Among potentially inhibitory compounds,
only sodium azide at a concentration of 10 mM partially
inhibited extracellular hydrolysis of ATP and to a higher ex-
tent ADP, by 35% and 48%, respectively. Mg2 and Ca2
were equally e¡ective in activating ecto-ATP hydrolysis, but
the presence of divalent cations was obligatory since 5 mM
EDTA was strongly inhibitory. All these characteristics ^
broad nucleotide speci¢city, absence of strict selectivity to-
wards divalent cations and insensitivity to some common in-
hibitors (Table 1) ^ ¢ts the group of ecto-, or E-type, ATP-
hydrolysing enzymes [6], while the partial sensitivity to azide
suggests CD39 [16] as a candidate ATPDase expressed in
melanomas.
Flow cytometric analysis of CD39 expression in normal
melanocytes and several sublines of the FM3 melanoma
(Fig. 1) con¢rmed this assumption, since the pattern of ex-
pression of CD39 coincided with the enzymatic activity pat-
tern. Thus, according to the enzymatic characteristics and its
pattern of expression, CD39 is the major ATP- and ADP-
hydrolysing ecto-enzyme in melanomas. Furthermore, the
qualitative RT-PCR analysis (Fig. 2) suggests that CD39 ex-
pression is controlled at the level of transcription (compare
Figs. 1 and 2). The level of CD39 mRNA is highest in the
di¡erentiated FM3.D subline, and low in normal melanocytes
and in the progressed melanoma subline FM3.P.
Despite the obvious advantages of using sublines of the
same tumor cell culture, this approach could cause certain
artifacts based on cell culture. In order to exclude this possi-
bility, unrelated melanoma cell lines were compared according
to their morphological characteristics and expressed ecto-AT-
Pase activity (Table 2). All melanomas having a dendritic
morphology as a morphological indicator of di¡erentiation,
exhibited an ecto-ATPase activity which was higher than
8 mU/106 cells, while the majority (9/11) of the progressed
melanomas exhibited a low enzymatic activity, ranging be-
tween 0.2^2.7 mU/106 cells (Table 2). Taken together, these
results demonstrate that overexpression of ecto-ATPDase/
CD39 is a marker of di¡erentiation in melanomas.
Incubation of melanoma cells with mABs to CD39 de-
creased ecto-ATPase activity by 24% as compared to unre-
lated mABs to biotin (Table 1). Similarly, these antibodies
induced decrease by approximately 30% of ecto-ATPase ac-
tivity of EBV-transformed B cells (not shown). In these cells
the high expression of CD39 and its involvement in the reg-
ulation of homotypic adhesion was ¢rst demonstrated [7].
Since mABs to CD39 are known to induce homotypic adhe-
sion [7] and decrease ecto-ATPase activity, we propose that
CD39/ecto-ATPDase may be a negative regulator of reversi-
ble adhesive interactions supporting the de-adhesion step.
4. Discussion
It has been noted that the speci¢c ecto-ATPase activity in
melanomas varies signi¢cantly between individual tumors [17].
The present results demonstrate that the state of tumor pro-
gression may de¢ne the level of expressed activity due to tran-
scriptional regulation of CD39/ecto-ATPDase, while several
other possible mechanisms of regulating the enzymatic activity
obviously can not be excluded.
Extracellular nucleotides are released from many di¡erent
cells [5], and elevated levels of extracellular ATP has been
observed in many tumors, one of the release mechanisms pre-
sumably utilizing overexpressed P-glycoprotein [18,19]. An ex-
ample is cytotoxic T-lymphocytes (CTL) that have been
shown to release ATP upon T cell receptor activation [20].
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Fig. 2. CD39 RT-PCR products from melanoma FM3 cell sublines.
The arrow indicates the position of the CD39 RT-PCR product.
EBV-B and K562 cells were used as positive and negative controls
for CD39 expression, respectively. GAPDH (upper band) was in-
cluded as an internal control. M, 100 bp ladder.
Table 2





Normal melanocytes D/S 1.38 þ 0.12
FM59 P/D 9.62 þ 0.77
FM87 D 8.23 þ 0.65
FM91.2 D/P 8.62 þ 0.60
FM91.5 D/P 14.10 þ 1.22
FM94 P/D 41.40 þ 3.30
FM97 S/D 13.14 þ 1.05
FM2 P 9.18 þ 0.71
FM6 P/S 0.81 þ 0.06
FM9 P 1.28 þ 0.10
FM28.4 P/E 7.30 þ 0.61
FM39 P 2.68 þ 0.11
FM45 P 1.92 þ 0.13
FM55p P 1.31 þ 0.10
FM55M1 P 1.72 þ 0.14
FM57 P 0.81 þ 0.05
FM76 P 2.60 þ 0.14
FM81 P 0.21 þ 0.02
aD, dendritic; P, polygonal; S, spindle; E, epithelioid.
bmU, nmol Pi enzymatically released from ATP per 1 min at 37‡C.
Values are means þ S.D. from at least three independent experiments.
K.N. Dzhandzhugazyan et al./FEBS Letters 430 (1998) 227^230 229
Overexpression at the cell surface of any ATP-hydrolysing
enzyme obviously can in£uence the process of purinergic sig-
nal transduction as well as ecto-phosphorylation. However,
adhesion is another phenomenon often coupled to particular
ATPDases [6] ^ either directly, via intrinsic ecto-ATPDase
activity exhibited by some known adhesion molecules, e.g.
NCAM [13], or indirectly, via both integrin-dependent and
-independent adhesion pathways, as shown by homotypic ad-
hesion triggered by monoclonal antibodies against CD39 [7].
Based on inhibitory e¡ect of these antibodies on the enzy-
matic activity, we propose that CD39 may be a negative reg-
ulator of cell adhesion, capable to reduce the strength of cell
contacts during binding or hydrolysis of ATP. The recently
demonstrated enhancement of adhesive interactions between
neutrophils and endothelial cells in the presence of suramin
[21], a known inhibitor of ecto-ATPases and antagonist of
purinoceptors [5,6], is in agreement with the proposed role
for ecto-ATPase. Obviously this hypothesis requires direct
proof, but is consistent with the observation that CTL with
a lower level of CD39 expression shows higher unspeci¢c cy-
totoxicity [22]. Furthermore, it has been demonstrated using
melanoma FM3 sublines that the cytotoxicity of various CTL
clones speci¢c to di¡erent groups of melanoma-associated
antigens increases during melanoma progression [10]. This
prompted us to search for immune escape mechanisms at
early steps of tumor progression, but the expression of several
proteins potentially involved in the immune escape (TAP 1/2,
LMP-2, LMP-7, HLA class I molecules, etc.) did not show
signi¢cant di¡erences between di¡erentiated and progressed
tumors [4,10]. However, the present results indicate that over-
expression of CD39/ecto-ATPDase in di¡erentiated melano-
mas might provide a mechanism enabling the escape from
immune surveillance by disrupting tumor cell contacts with
CTL.
The question arises if the expression pattern demonstrated
here for ecto-ATPDase/CD39 is common also for expression
of ecto-ATPases in other tumors. Similar observations on
ecto-ATPase activity have been made in experimental carcino-
genesis of rat and mouse hepatic parenchyma [23,24] and the
role of elevated ecto-ATPase activity in overcoming contact
inhibition has been proposed [23], but it has not been eluci-
dated which protein was responsible for this enzymatic activ-
ity. Previously, CD39 as a major ecto-ATP-hydrolysing en-
zyme has been assigned to activated immune cells,
endothelial cells and highly vascularized tissues [16]. To our
knowledge, overexpression of ecto-ATPase activity and CD39
was reported here for the ¢rst time using human tumor cell
lines.
The mechanism of down-regulation of the enzymatic activ-
ity and expression of CD39 during tumor progression is not
clear. In this connection it should be noted that the genetic
events involving chromosome region 10q22-10qter may be
associated with tumor progression [2,3]. The established local-
ization of CD39/ecto-ATPDase gene to the region 10q23.1-
10q24.1 [25] could possibly be related to changes in CD39
expression during tumor progression. The elucidation of the
role of CD39/ecto-ATPDase in immunological escape mecha-
nisms will require further studies focused on the biological
consequences of the manipulation of ecto-ATPase activity
and the level of CD39 expression.
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